ShannonRMorrisMD

PubMed

• 18 citations
  Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer:...
  Renata Ferrarotto, Ian Anderson, Balazs Medgyasszay, Maria Rosario García-Campelo, William Jeffery Edenfield, Trevor M. Feinstein, Jennifer Johnson, Sujith Kalmadi, Ph...> ;Cancer Medicine. 2021 Sep 1
• 39 citations
  Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, pl...
  Davey B. Daniel, Vladimer Kuchava, Igor Bondarenko, Oleksandr Ivashchuk, Sreekanth Reddy, Jana Jaal, Iveta Kudaba, Lowell L. Hart, Amiran Matitashvili, Yili Pritchett,...> ;International Journal of Cancer. 2021 May 15
• 31 citations
  Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results f...
  Jared Weiss, Jerome H. Goldschmidt, Z. Andric, Konstantin H. Dragnev, Chad Gwaltney, Konstantina Skaltsa, Yili Pritchett, Joyce M Antal, Shannon R. Morris, Davey B. Da...> ;Clinical Lung Cancer. 2021 Mar 26
• 64 citations
  Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
  Lowell L. Hart, Renata Ferrarotto, Z. Andric, J. Thaddeus Beck, Janakiraman Subramanian, Davorin Radosavljevic, Bojan Zaric, Wahid Hanna, Raid Aljumaily, Taofeek K. Ow...> ;Advances in Therapy. 2021 Jan 1
• 63 citations
  Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
  Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael A. Danso, Lazar Popovic, Timothy J. Pluard, Hyo S Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald A. Richa...> ;The Lancet. Oncology. 2019 Nov 1
• 91 citations
  Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.
  Jared Weiss, Tibor Csoszi, M. Maglakelidze, Robert Hoyer, J.T. Beck, M. Domine Gomez, A. Lowczak, Raid Aljumaily, C.M. Rocha Lima, Ralph V. Boccia, Wahid Hanna, Petros...> ;Annals of Oncology. 2019 Oct 1
• 31 citations
  A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients...
  Carol Aghajanian, Katherine M. Bell-McGuinn, Howard A. Burris, Lillian L. Siu, Lee Ann Stayner, Jennifer J. Wheler, David S. Hong, Carla Kurkjian, Shubham Pant, Ademi ...> ;Investigational New Drugs. 2018 Apr 3
• 13 citations
  A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
  Robert J. Arceci, Carl E. Allen, Ira J. Dunkel, Eric D. Jacobsen, James A. Whitlock, Robert Vassallo, Shannon R. Morris, Alison Portnoy, Beth Ann Reedy, Deborah A. Smi...> ;Pediatric Blood & Cancer. 2017 May 1
• Multidimensional daily diary of fatigue-fibromyalgia-17 items (MDF-fibro-17). part 1: development and content validity.
  Morris, S.,Li, Y.,Smith, JAM.,Dube', S.,Burbridge, C.,Symonds, T.> ;BMC Musculoskelet Disord. 2017 May 18
• 60 citations
  First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies
  Pamela N. Munster, Rahul Aggarwal, David S. Hong, Jan H.M. Schellens, Ruud van der Noll, Jennifer M. Specht, Petronella O. Witteveen, Theresa L. Werner, E. Claire Dees...> ;Clinical Cancer Research. 2016 Apr 15
• 24 citations
  Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies
  Hatice Gungor, Azeem Saleem, Syed Babar, Roberto Dina, Mona El-Bahrawy, Edward Curry, Nona Rama, Michele Chen, Emily Pickford, Roshan Agarwal, Sarah P. Blagden, Sabin ...> ;Journal of Nuclear Medicine. 2015 Dec 1
• 18 citations
  A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro , in vivo and clinical data identifies the importance of modulation of ...
  Azadeh Cheraghchi-Bashi, Christine A. Parker, Edward Curry, Jean Frederic Salazar, Hatice Gungor, Azeem Saleem, Paula Cunnea, Nona Rama, Cristian Salinas, Gordon B. Mi...> ;Oncotarget. 2015 Oct 19
• 93 citations
  The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
  Andrew Spencer, Sung-Soo Yoon, Simon J. Harrison, Shannon R. Morris, Deborah A. Smith, Richard A. Brigandi, Jennifer Gauvin, Rakesh Kumar, Joanna Opalinska, Christine ...> ;Blood. 2014 Oct 2
• 4 citations
  Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer
  Uday B. Dandamudi, Laurel M. Adams, Brendan M. Johnson, John W. Bauman, Shannon R. Morris, Sharon C. Murray, R. Timothy Webb, Elaina M. Gartner, Raymond J. Hohl, Lione...> ;Cancer Chemotherapy and Pharmacology. 2011 Apr 1
• Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.
  Lyndon C. Kirby, Brendan M. Johnson, Laurel M. Adams, Derek J. Eberwein, Ke Zhang, Sharon C. Murray, Christian D. Lates, Robert A. Blum, Shannon R. Morris> ;Journal of Clinical Pharmacology. 2010 May 1
• 43 citations
  Gene expression profiling in breast cancer
  Shannon Morris, Lisa A. Carey> ;Current Opinion in Oncology. 2007 Nov 1
• 31 citations
  Molecular profiling in breast cancer
  Shannon R. Morris, Lisa A. Carey> ;Reviews in Endocrine & Metabolic Disorders. 2007 Apr 27
• 10 citations
  Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
  Shannon R. Morris, Lisa A. Carey> ;Oncology. 2006 Dec 1
• 13 citations
  Acute liver failure due to natural killer-like T-cell leukemia/lymphoma: A case report and review of the Literature
  Evan S. Dellon, Shannon Morris, Wozhan Tang, Cherie H. Dunphy, Mark W. Russo> ;World Journal of Gastroenterology. 2006 Jul 7
• 2 citations
  Selection of functional mutations in the U5-IR stem and loop regions of the Rous sarcoma virus genome
  Michael Johnson, Shannon Morris, Aiping Chen, Ed Stavnezer, Jonathan Leis> ;BMC Biology. 2004 May 20
• 19 citations
  Replication of Avian Sarcoma Virus In Vivo Requires an Interaction between the Viral RNA and the TψC Loop of the tRNATrp Primer
  Shannon Morris, Michael E. Johnson, Ed Stavnezer, Jonathan Leis> ;Journal of Virology. 2002 Aug 1
• 21 citations
  Changes in Rous sarcoma virus RNA secondary structure near the primer binding site upon tRNATrp primer annealing.
  Shannon Morris, Jonathan Leis> ;Journal of Virology. 1999 Aug 1
• 23 citations
  Multiple biological roles associated with the Rous sarcoma virus 5' untranslated RNA U5-IR stem and loop.
  Jennifer T. Miller, Zheng Ge, Shannon Morris, Kingshuk Das, Jonathan Leis> ;Journal of Virology. 1997 Oct 1
• Join now to see all